The use of early adjuvant aromatase inhibitor therapy : Contributions from the BIG 1-98 letrozole trialFORBES, John F.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S2-S7, SUP7Article

From tamoxifen to letrozole: changing paradigms for the treatment of hormone-sensitive breast cancerPEREZ, Edith A; FORBES, John F.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, 27 p., SUP7Serial Issue

Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy : A Z-FAST updateBRUFSKY, Adam.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S13-S17, SUP7Article

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane StudyBLISS, Judith M; KILBURN, Lucy S; DE VELDE, Cornelis J. H. Van et al.Journal of clinical oncology. 2012, Vol 30, Num 7, pp 709-717, issn 0732-183X, 9 p.Article

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancerSESTAK, Ivana; HARVIE, Michelle; HOWELL, Anthony et al.Breast cancer research and treatment. 2012, Vol 134, Num 2, pp 727-734, issn 0167-6806, 8 p.Article

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 StudyCOLLEONI, Marco; GIOBBIE-HURDER, Anita; CHIRGWIN, Jacquie et al.Journal of clinical oncology. 2011, Vol 29, Num 9, pp 1117-1124, issn 0732-183X, 8 p.Article

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataCUZICK, Jack; SESTAK, Ivana; MERSHON, John et al.Lancet (British edition). 2013, Vol 381, Num 9880, pp 1827-1834, issn 0140-6736, 8 p.Article

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast CancerCUZICK, Jack; DOWSETT, Mitch; HOWELL, Anthony et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4273-4278, issn 0732-183X, 6 p.Article

Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategyBRADBURY, Andrew W; ADAM, Donald J; BELL, Jocelyn et al.Journal of vascular surgery. 2010, Vol 51, Num 5, issn 0741-5214, 5S-17S, SUPArticle

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer : Update of study BIG 1-98COATES, Alan S; KESHAVIAH, Aparna; LDNG, Istvdn et al.Journal of clinical oncology. 2007, Vol 25, Num 5, pp 486-492, issn 0732-183X, 7 p.Article

Sitting Time and Waist Circumference Are Associated With Glycemia in U.K. South Asians: Data from 1,228 adults screened for the PODOSA trialGILL, Jason M. R; BHOPAL, Raj; LEAN, Michael E. J et al.Diabetes care. 2011, Vol 34, Num 5, pp 1214-1218, issn 0149-5992, 5 p.Article

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast CancerSTOCKLER, Martin R; HARVEY, Vernon J; CORONA GAINFORD, M et al.Journal of clinical oncology. 2011, Vol 29, Num 34, pp 4498-4504, issn 0732-183X, 7 p.Article

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical FactorsGONG TANG; CUZICK, Jack; COSTANTINO, Joseph P et al.Journal of clinical oncology. 2011, Vol 29, Num 33, pp 4365-4372, issn 0732-183X, 8 p.Article

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93PAGANI, Olivia; GELBER, Shari; THURLIMANN, Beat et al.Breast cancer research and treatment. 2009, Vol 116, Num 3, pp 491-500, issn 0167-6806, 10 p.Article

Preventing relapse beyond 5 years : The MA.17 extended adjuvant trialGOSS, Paul E.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S8-S12, SUP7Article

Reproducibility of visual assessment on mammographic densityJINNAN GAO; WARREN, Ruth; WARREN-FORWARD, Helen et al.Breast cancer research and treatment. 2008, Vol 108, Num 1, pp 121-127, issn 0167-6806, 7 p.Article

Choosing between endocrine therapy and chemotherapy - or is there a role for combination therapy?FORBES, John F; GRADISHAR, William J; RAVDIN, Peter M et al.Breast cancer research and treatment. 2002, Vol 75, pp S37-S44, issn 0167-6806, SUP1Article

Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination TrialRING, Alistair; SESTAK, Ivana; BAUM, Michael et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4266-4272, issn 0732-183X, 7 p.Article

Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC TrialSESTAK, Ivana; DISTLER, Wolfgang; FORBES, John F et al.Journal of clinical oncology. 2010, Vol 28, Num 21, pp 3411-3415, issn 0732-183X, 5 p.Article

The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in Breast CancerKARLSSON, Per; COLE, Bernard F; FEY, Martin F et al.Journal of clinical oncology. 2007, Vol 25, Num 15, pp 2019-2026, issn 0732-183X, 8 p.Article

Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen : Safety Analysis of BIG 1-98 TrialMOURIDSEN, Henning; KESHAVIAH, Aparna; GELBER, Richard D et al.Journal of clinical oncology. 2007, Vol 25, Num 36, pp 5715-5722, issn 0732-183X, 8 p.Article

Future directions in the treatment of hormone-sensitive advanced breast cancer : The RAD001 (everolimus)-letrozole clinical programLANE, Heidi A; LEBWOHL, David.Seminars in oncology. 2006, Vol 33, Num 2, issn 0093-7754, S18-S25, SUP7Article

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialCUZICK, Jack; SESTAK, Ivana; BONANNI, Bernardo et al.Lancet (British edition). 2014, Vol 383, Num 9922, pp 1041-1048, issn 0140-6736, 8 p.Article

Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 TrialEWERTZ, Marianne; GRAY, Kathryn P; GELBER, Richard D et al.Journal of clinical oncology. 2012, Vol 30, Num 32, pp 3967-3975, issn 0732-183X, 9 p.Article

Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control StudyCUZICK, Jack; WARWICK, Jane; PINNEY, Elizabeth et al.Journal of the National Cancer Institute. 2011, Vol 103, Num 9, pp 744-752, issn 0027-8874, 9 p.Article